Certain identified information has been excluded from the exhibit because it is both not material and is the type that the registrant treats as private or confidential.] MASTER TRADEMARK ASSIGNMENT AGREEMENTMaster Trademark Assignment Agreement • August 3rd, 2022 • Intercept Pharmaceuticals, Inc. • Pharmaceutical preparations
This Master Trademark Assignment Agreement (this “Assignment”) is made and entered into effective as of May 5, 2022 (the “Execution Date”) and effective as of the Completion (as defined below) (the “Effective Date”) by and among Intercept Pharmaceuticals, Inc., a company incorporated in Delaware, and RXF Technologies, Inc., a company incorporated in Delaware (collectively, the “Sellers”), and Mercury Pharma Group Limited, a company incorporated in England (the “Purchaser”). The Sellers and the Purchaser are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
